This move marks a first in the healthcare sector, aimed at strengthening drug security and ensuring a more stable supply of medicines.
Emirates Drug Establishment has announced new measures to end the monopoly of medical products in the UAE.
Under the new mechanism, pharmaceutical companies will be required to appoint more than one agent for each medical product.
This initiative is the first of its kind in the healthcare sector, aimed at enhancing drug security.
The new mechanism is designed to eliminate monopolistic practices and ensure the continuous availability of medical products.
It also helps minimize the risk of supply disruptions during emergencies and crises.
Additionally, it promotes pharmaceutical investment and strengthens the UAE’s global competitiveness.
